Clustered Vesicles on the Neck

Delice Kayishunge, MD, MSc; Benjamin T. Rollins, MD; Laura A. Gonzalez-Krellwitz, MD; Megan S. Evans, MD

Eligible for 1 MOC SA Credit From the ABD

This Photo Challenge in our print edition is eligible for 1 self-assessment credit for Maintenance of Certification from the American Board of Dermatology (ABD). After completing this activity, diplomates can visit the ABD website (http://www.abderm.org) to self-report the credits under the activity title "*Cutis* Photo Challenge." You may report the credit after each activity is completed or after accumulating multiple credits.



A 6-year-old girl presented to the dermatology clinic with a rash on the right side of the neck that was noted at birth as a small raised lesion but slowly increased over time in size and number of lesions. She reported pruritus and irritation, particularly when rubbed or scratched. There was no family history of similar skin abnormalities. Her medical history was notable for a left-sided cholesteatoma on tympanomastoidectomy. Physical examination revealed clustered vesicles on the right side of the neck with underlying erythema. The vesicles contained mostly clear fluid with a few focal areas of hemorrhagic fluid. Ultrasonography was unremarkable, and magnetic resonance imaging revealed superficial T2 hyperintense nonenhancing cutaneous and subcutaneous lesions overlying the right lateral neck with minimal extension into the superficial right supraclavicular soft tissues.

WHAT'S YOUR **DIAGNOSIS?**

- a. dermatitis herpetiformis
- b. extragenital bullous lichen sclerosus
- c. herpes zoster virus
- d. macrocystic lymphatic malformation
- e. microcystic lymphatic malformation

PLEASE TURN TO PAGE 246 FOR THE DIAGNOSIS

From the University of Arkansas for Medical Sciences, Little Rock. Dr. Kayishunge is from the College of Medicine, Drs. Rollins and Gonzalez-Krellwitz are from the Department of Pathology, and Dr. Evans is from the Department of Dermatology. The authors report no conflict of interest.

Correspondence: Delice Kayishunge, MD, MSc, 4301 W Markham St, Slot 576, Little Rock, AR 72205 (dkayishunge@uams.edu). doi:10.12788/cutis.0890

Copyright Cutis 2023. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

THE **DIAGNOSIS:** Microcystic Lymphatic Malformation

A punch biopsy demonstrated anastomosing fluidfilled spaces within the papillary and reticular dermal layers (Figure), confirming the diagnosis of microcystic lymphatic malformation (LM)(formerly known as lymphangioma circumscriptum), a congenital vascular malformation composed of slow-flow lymphatic channels.¹ The patient underwent serial excisions with improvement of the LM, though the treatment course was complicated by hypertrophic scar formation.

The classic clinical presentation of microcystic LM includes a crop of vesicles containing clear or hemorrhagic fluid with associated oozing or bleeding.² When cutaneous lesions resembling microcystic LM develop in response to lymphatic damage and resulting stasis, such as from prior radiotherapy or surgery, the term *lymphangiectasia* is used to distinguish this entity from congenital microcystic LM.³

Microcystic LMs are histologically indistinguishable from macrocystic LMs; however, macrocystic LMs typically are clinically evident at birth as ill-defined subcutaneous masses.^{2,4-6} Dermatitis herpetiformis, a dermatologic manifestation of gluten sensitivity, causes intensely pruritic vesicles in a symmetric distribution on the elbows, knees, and buttocks. Histopathology shows neutrophilic microabscesses in the dermal papillae with subepidermal blistering. Direct immunofluorescence demonstrates the deposition of IgA along the basement membrane with dermal papillae aggregates.⁶The underlying dermis also may contain a lymphohistiocytic infiltrate rich in neutrophils. The vesicles of herpes zoster virus are painful and present in a dermatomal distribution. A viral cytopathic effect often is observed in keratinocytes, specifically with multinucleation, molding, and margination of chromatin material. The lesions are accompanied by variable lymphocytic inflammation and epithelial necrosis resulting in intraepidermal blistering.7 Extragenital lichen sclerosus presents as polygonal white papules merging to form plaques and may include hemorrhagic blisters in some instances. Histopathology shows hyperkeratosis, epidermal atrophy with flattened rete ridges, vacuolar interface changes, loss of elastic fibers, and hyalinization of the lamina propria with lymphocytic infiltrate.8

Endothelial cells in LM exhibit activating mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene, *PIK3CA*, which may lead to proliferation and overgrowth of the lymphatic vasculature, as well as increased production of cyclic guanosine monophosphate.^{9,10} Phosphodiesterase 5 (PDE5) is expressed in the perivascular smooth muscle adjacent to lymphatic spaces in LMs but not in the their vasculature.¹⁰ This pattern of PDE5 expression may cause perilesional vasculature to constrict, preventing lymphatic fluid from draining into the veins.¹¹ It is theorized that the PDE5 inhibitor sildenafil leads to relaxation of the vasculature adjacent to LMs, allowing the outflow of the accumulated lymphatic fluid and thus decompression.¹¹⁻¹³

Management of LM should not only take into account the depth and location of involvement but also any associated symptoms or complications, such as pruritus, pain, bleeding, or secondary infections. Magnetic resonance imaging (MRI) typically has been considered the gold standard for determining the size and depth of involvement of the malformation.^{1,3,4} However, ultrasonography with Doppler flow may be considered an initial diagnostic and screening test, as it can distinguish between macrocystic and microcystic lesions, which are below the resolution capacity of MRI.⁴ Notably, our patient's LM was undetectable on ultrasonography and was found to be largely superficial in nature on MRI.

Serial excision of the microcystic LM was conducted in our patient, but there currently is no consensus on optimal treatment of LM, and many treatment options are complicated by high recurrence rates or complications.⁵ Procedural approaches may include excision, cryotherapy, radiotherapy, sclerotherapy, or laser therapy, while pharmacologic approaches may include sildenafil for its inhibition of PDE5 or sirolimus (oral or topical) for its inhibition of mammalian target of rapamycin.^{5,12-14} Because recurrence is highly likely, patients may require repeat treatments or a combination approach to therapy.^{1,5} The development of targeted therapies may lead to a shift in management of LMs in the future, as successful



An unencapsulated proliferation of anastomosing vascular spaces within the papillary and reticular dermis (H&E, original magnification $\times 20$).

Copyright Cutis 2023. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

use of the *PIK3CA* inhibitor alpelisib recently has been reported to lead to clinical improvement of *PIK3CA*-related LMs, including in patients with *PIK3CA*-related overgrowth syndromes.¹⁵

REFERENCES

- 1. Garzon MC, Huang JT, Enjolras O, et al. Vascular malformations: part I. J Am Acad Dermatol. 2007;56:353-374. doi:10.1016/j.jaad.2006.05.069
- Alrashdan MS, Hammad HM, Alzumaili BAI, et al. Lymphangioma circumscriptum of the tongue: a case with marked hemorrhagic component. J Cutan Pathol. 2018;45:278-281. doi:10.1111/cup.13101
- Osborne GE, Chinn RJ, Francis ND, et al. Magnetic resonance imaging in the investigation of penile lymphangioma circumscriptum. Br J Dermatol. 2000;143:467-468. doi:10.1046/j.1365-2133.2000.03695.x
- Davies D, Rogers M, Lam A, et al. Localized microcystic lymphatic malformations—ultrasound diagnosis. *Pediatr Dermatol.* 1999;16: 423-429. doi:10.1046/j.1525-1470.1999.00110.x
- García-Montero P, Del Boz J, Baselga-Torres E, et al. Use of topical rapamycin in the treatment of superficial lymphatic malformations. *J Am Acad Dermatol.* 2019;80:508-515. doi:10.1016/j.jaad.2018.09.050
- Clarindo MV, Possebon AT, Soligo EM, et al. Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment. *An Bras Dermatol.* 2014;89:865-875; quiz 876-877. doi:10.1590/abd1806-4841.20142966
- Leinweber B, Kerl H, Cerroni L. Histopathologic features of cutaneous herpes virus infections (herpes simplex, herpes varicella/zoster): a broad spectrum of presentations with common pseudolymphomatous aspects. *Am J Surg Pathol.* 2006;30:50-58.

- Shiver M, Papasakelariou C, Brown JA, et al. Extragenital bullous lichen sclerosus in a pediatric patient: a case report and literature review. *Pediatr Dermatol.* 2014;31:383-385. doi:10.1111 /pde.12025
- Blesinger H, Kaulfuß S, Aung T, et al. *PIK3CA* mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations [published online July 9, 2018]. *PLoS One.* 2018;13:E0200343. doi:10.1371/journal.pone.0200343
- Green JS, Prok L, Bruckner AL. Expression of phosphodiesterase-5 in lymphatic malformation tissue. *JAMA Dermatol.* 2014;150:455-456. doi:10.1001/jamadermatol.2013.7002
- Swetman GL, Berk DR, Vasanawala SS, et al. Sildenafil for severe lymphatic malformations. N Engl J Med. 2012;366:384-386. doi:10.1056 /NEJMc1112482
- Tu JH, Tafoya E, Jeng M, et al. Long-term follow-up of lymphatic malformations in children treated with sildenafil. *Pediatr Dermatol*. 2017;34:559-565. doi:10.1111/pde.13237
- Maruani A, Tavernier E, Boccara O, et al. Sirolimus (rapamycin) for slow-flow malformations in children: the Observational-Phase Randomized Clinical PERFORMUS Trial. JAMA Dermatol. 2021;157:1289-1298. doi:10.1001/jamadermatol.2021.3459
- Delestre F, Venot Q, Bayard C, et al. Alpelisib administration reduced lymphatic malformations in a mouse model and in patients. *Sci Transl Med.* 2021;13:eabg0809. doi:10.1126/scitranslmed .abg0809
- Garreta Fontelles G, Pardo Pastor J, Grande Moreillo C. Alpelisib to treat CLOVES syndrome, a member of the *PIK3CA*-related overgrowth syndrome spectrum [published online February 21, 2022]. *Br J Clin Pharmacol.* 2022;88:3891-3895. doi:10.1111/bcp.15270

Copyright Cutis 2023. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.